Study guide
10.4 Fatty Acid Synthesis, Beta-Oxidation, Ketogenesis, and Lipoprotein Transport
NPLEX Part I — Biomedical Sciences Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Pacing, and GEA Strategy
1.1 Overview of NPLEX Part I & NABNE Exam Structure 1.2 Deconstructing Biomedical Clinical Vignettes 1.3 General Exam Areas (GEAs) & Passing Standards
2 Chapter 2: Gross Anatomy & Musculoskeletal System
2.1 Musculoskeletal Anatomy of Upper and Lower Extremities 2.2 Structural Anatomy of Head, Neck, Thorax, and Abdomen 2.3 Pelvic Architecture, Perineal Anatomy, and Articular Structures
3 Chapter 3: Histology & Microscopic Anatomy
3.1 Histology of Epithelial, Connective, and Muscular Tissues 3.2 Microscopic Structure of Gastrointestinal, Renal, and Endocrine Organs 3.3 Microscopic Anatomy of Integument, Lymphoid Tissues, and Respiratory Epithelium
4 Chapter 4: Neuroanatomy & Special Senses
4.1 Cranial Nerves, Nuclei, and Peripheral Distribution 4.2 Spinal Cord Tracts, Brainstem Circuits, and Motor/Sensory Pathways 4.3 Cerebral Cortex, Basal Ganglia, Limbic System, and Autonomic Nervous System 4.4 Neuroanatomy of Vision, Audition, Vestibular Function, and Olfaction/Gustation
5 Chapter 5: Embryology & Developmental Anatomy
5.1 Gametogenesis, Fertilization, Blastulation, and Germ Layer Derivatives 5.2 Organogenesis: Cardiovascular and Respiratory System Development 5.3 Gastrointestinal, Urogenital, and Craniofacial Embryology
6 Chapter 6: Cellular & General Physiology
6.1 Membrane Transport Mechanics, Resting Potentials, and Ion Channels 6.2 Action Potential Propagation and Synaptic Transmission 6.3 Excitation-Contraction Coupling in Skeletal, Cardiac, and Smooth Muscle
7 Chapter 7: Cardiovascular & Respiratory Physiology
7.1 Cardiac Electrophysiology, ECG, and Mechanical Cardiac Cycle 7.2 Hemodynamics, Peripheral Resistance, and Blood Pressure Control 7.3 Pulmonary Mechanics, Lung Volumes, and Gas Exchange Dynamics 7.4 Transport of Oxygen/CO2 and Neural/Chemical Control of Breathing
8 Chapter 8: Renal, Fluid, & Acid-Base Physiology
8.1 Glomerular Filtration Rate and Tubular Reabsorption/Secretion Mechanics 8.2 Countercurrent Multiplication, Osmoregulation, and Urine Concentration 8.3 Body Fluid Compartments, Sodium/Water Homeostasis, and Potassium Dynamics 8.4 Renal & Respiratory Acid-Base Regulation and Compensation Mechanisms
9 Chapter 9: Gastrointestinal, Endocrine, & Reproductive Physiology
9.1 GI Motility, Secretory Functions, Digestion, and Nutrient Absorption 9.2 Hypothalamic-Pituitary Axes, Adrenal Gland, and Thyroid Physiology 9.3 Endocrine Pancreas, Glucose Regulation, Calcium/Phosphate Homeostasis 9.4 Male and Female Reproductive Endocrinology and Menstrual Cycle Regulation
10 Chapter 10: Enzymology, Bioenergetics, & Carbohydrate/Lipid Metabolism
10.1 Enzyme Kinetics, Catalytic Mechanisms, and Vitamin Cofactors 10.2 Glycolysis, Pyruvate Dehydrogenase, TCA Cycle, and Oxidative Phosphorylation 10.3 Glycogen Metabolism, Gluconeogenesis, and Pentose Phosphate Pathway 10.4 Fatty Acid Synthesis, Beta-Oxidation, Ketogenesis, and Lipoprotein Transport
11 Chapter 11: Amino Acid/Nucleotide Metabolism & Clinical Genetics
11.1 Amino Acid Degradation, Transamination, and Urea Cycle Disorders 11.2 Purine and Pyrimidine Synthesis, Salvage, and Gout Pathophysiology 11.3 Mendelian Inheritance, Chromosomal Abnormalities, and Molecular Genetics
12 Chapter 12: Immunology & Immunopathology
12.1 Innate Immune Barriers, Phagocytosis, Cellular Pattern Recognition, and Complement System 12.2 Adaptive Immunity: T-Cell & B-Cell Activation, MHC Restriction, and Antibodies 12.3 Types I-IV Hypersensitivity Reactions and Mechanisms of Autoimmunity 12.4 Immunodeficiency Syndromes, Tumor/Transplant Immunology, and Vaccine Types
13 Chapter 13: Medical Microbiology
13.1 Medical Bacteriology: Gram-Positive, Gram-Negative, and Atypical Bacteria 13.2 Medical Virology: DNA, RNA, Retroviruses, and Viral Pathogenesis 13.3 Medical Mycology: Cutaneous, Systemic, and Opportunistic Fungal Infections 13.4 Medical Parasitology: Protozoan and Helminthic Pathogens
14 Chapter 14: General Pathology & Neoplasia
14.1 Cellular Adaptation, Reversible/Irreversible Injury, Necrosis, and Apoptosis 14.2 Acute and Chronic Inflammation, Chemical Mediators, and Tissue Healing 14.3 Neoplasia: Benign vs Malignant Features, Carcinogenesis, Oncogenes, and Tumor Suppressors
15 Chapter 15: Systems Pathology & Disease Mechanisms
15.1 Pathophysiology of Atherosclerosis, Heart Failure, COPD, and Pneumonias 15.2 Glomerulonephritis, Inflammatory Bowel Disease, and Hepatorenal Disease Pathophysiology 15.3 Endocrine Disorders, Neurodegenerative Pathology, and Epidemiological Principles 15.4 Hematopoietic System Pathology: Anemias, Coagulopathies, and Hematologic Neoplasms 15.5 Immunological System Pathology: Autoimmune, Amyloid, and Systemic Immune-Mediated Disease 15.6 Integumentary System Pathology: Inflammatory Dermatoses, Blistering Disorders, and Skin Neoplasms 15.7 Musculoskeletal System Pathology: Metabolic Bone Disease, Arthropathies, and Bone Neoplasms 15.8 Reproductive System Pathology: Endocrine, Inflammatory, and Neoplastic Disorders of the Reproductive Tract
10.4 Fatty Acid Synthesis, Beta-Oxidation, Ketogenesis, and Lipoprotein Transport
Key Takeaways Explain This Topic AI
Fatty acid synthesis occurs in the cytosol from acetyl-CoA via the citrate shuttle, governed by the rate-limiting enzyme Acetyl-CoA Carboxylase (ACC), which requires Biotin (B7) and is activated by citrate/insulin.
Fatty acid beta-oxidation occurs in the mitochondrial matrix via the carnitine shuttle (CPT-I rate-limiting, inhibited by malonyl-CoA); MCAD deficiency causes hypoketotic hypoglycemia during fasting.
Ketogenesis in liver mitochondria produces acetoacetate, beta-hydroxybutyrate, and acetone under high acetyl-CoA conditions, serving as alternative fuel for extrahepatic tissues during starvation or DKA.
Lipoproteins transport hydrophobic lipids: Chylomicrons (ApoB-48, dietary lipids), VLDL (ApoB-100, endogenous liver triglycerides), LDL (ApoB-100, cholesterol to tissues via LDLR), and HDL (ApoA-I, reverse cholesterol transport via LCAT).
Last updated: July 2026
10.4 Fatty Acid Synthesis, Beta-Oxidation, Ketogenesis, and Lipoprotein Transport
Lipids represent the body's major energy reserve and essential structural components of biological membranes. Lipid metabolism involves coordinated synthesis (lipogenesis), degradation ( β \beta β -oxidation), ketone body formation (ketogenesis), and systemic transport via specialized lipoprotein particles. Understanding these biochemical processes and their pathology is crucial for the NPLEX Part I exam.
Fatty Acid Synthesis (De Novo Lipogenesis)
Occurring primarily in the cytosol of liver and lactating mammary gland cells during the fed state, de novo lipogenesis converts excess dietary carbohydrate into long-chain fatty acids (primarily Palmitate, 16C).
The Citrate Shuttle
Acetyl-CoA produced in the mitochondrial matrix cannot cross the inner mitochondrial membrane directly. Under high energy charges, accumulated citrate is exported to the cytosol via the citrate shuttle :
Cytosolic ATP-Citrate Lyase cleaves Citrate → \rightarrow → Acetyl-CoA + Oxaloacetate.
Rate-Limiting Step & Regulation
Rate-Limiting Enzyme: Acetyl-CoA Carboxylase (ACC) .
Reaction: Acetyl-CoA (2C) + HCO 3 − + ATP ⟶ + \text{HCO}_3^- + \text{ATP} \longrightarrow + HCO 3 − + ATP ⟶ Malonyl-CoA (3C) .
Cofactor Required: Biotin (Vitamin B7) .
Regulation:
Activated by: Insulin (dephosphorylation) and Citrate (allosteric polymerized active state).
Inhibited by: Glucagon / Epinephrine (PKA phosphorylation) and Palmitoyl-CoA (end-product feedback inhibition).
Fatty Acid Synthase Complex
A multifunctional homodimer utilizing NADPH (derived from the HMP shunt and Malic Enzyme) to sequentially elongate malonyl-CoA units, producing Palmitate (16:0).
Fatty Acid Oxidation ( β \beta β -Oxidation)
During fasting or exercise, free fatty acids released from adipose tissue via hormone-sensitive lipase are oxidized in the mitochondrial matrix to produce energy.
The Carnitine Shuttle
Long-chain fatty acids (LCFAs) in the cytosol are activated to Fatty Acyl-CoA by Acyl-CoA synthetase. Entry into the mitochondrial matrix requires the Carnitine Shuttle :
Carnitine Palmitoyltransferase-I (CPT-I / CAT-I): Located on the outer mitochondrial membrane. The rate-limiting enzyme of β \beta β -oxidation; converts Fatty Acyl-CoA + Carnitine → \rightarrow → Fatty Acylcarnitine.
Inhibition: Strongly inhibited by Malonyl-CoA (prevents simultaneous fatty acid synthesis and degradation).
Carnitine-Acylcarnitine Translocase: Translocates Fatty Acylcarnitine across inner membrane.
Carnitine Palmitoyltransferase-II (CPT-II): On inner membrane; regenerates Fatty Acyl-CoA and free carnitine in matrix. Cytosol Outer Membrane Inner Membrane Matrix
- Fatty Acyl-CoA + Carnitine ──[ CPT-I ]──► Fatty Acylcarnitine ──[ Translocase ]──► Fatty Acyl-CoA + Carnitine
- ▲ │
- Inhibited by β-Oxidation Cycle
- Malonyl-CoA │
- ▼
- Acetyl-CoA + NADH + FADH2
- The β \beta β -Oxidation Cycle
Each cycle shortens the acyl chain by 2 carbons, producing:
- 1 Acetyl-CoA (enters TCA cycle or ketogenesis)
- 1 NADH (enters ETC Complex I)
- 1 FADH 2 \text{FADH}_2 FADH 2 (enters ETC Complex II / ETF)
- Metabolic Disorders of β \beta β -Oxidation
Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency: Autosomal recessive defect in initial step of β \beta β -oxidation for 6-to-12 carbon fatty acids.
Presentation: Triggered by prolonged fasting or illness. Features hypoketotic hypoglycemia , lethargy, seizures, hepatomegaly, and sudden death. Laboratory shows elevated dicarboxylic acids in urine and low plasma ketones.
Systemic Primary Carnitine Deficiency: Defective carnitine transporter preventing LCFA entry into mitochondria. Hypoketotic hypoglycemia, hypotonia, and dilated cardiomyopathy.
Ketogenesis & Ketone Body Utilization
During prolonged starvation, low carbohydrate intake, or Diabetic Ketoacidosis (DKA), oxaloacetate in hepatocytes is consumed for gluconeogenesis. Accumulated Acetyl-CoA from massive β \beta β -oxidation exceeds TCA cycle capacity and is shunted into Ketogenesis within liver mitochondria .
Pathway & Key Enzymes
Rate-Limiting Enzyme: HMG-CoA Synthase (mitochondrial).
Ketone Body Products:
Acetoacetate: Primary ketone body.
β \beta β -Hydroxybutyrate: Most abundant circulating ketone body (reduced form of acetoacetate; measured in blood).
Acetone: Volatile breakdown product excreted via lungs, responsible for characteristic fruity breath odor.
Extrahepatic Utilization
Ketone bodies exit hepatocytes into blood and are converted back to Acetyl-CoA in peripheral tissues (brain, cardiac muscle, skeletal muscle) for ATP production. The liver cannot utilize ketone bodies because it lacks the enzyme Thiophorase (Succinyl-CoA:3-ketoacid CoA transferase / SCOT).
Lipoprotein Transport & Metabolism
Lipoproteins are spherical complexes transporting hydrophobic lipids (triglycerides, cholesterol esters) within a hydrophilic shell of phospholipids, free cholesterol, and apolipoproteins .
Summary of Lipoprotein Classes
Lipoprotein Primary Lipid Content Major Apolipoprotein(s) Primary Physiological Function
Chylomicron Dietary Triglycerides (85-90%) ApoB-48 , ApoC-II, ApoE Delivers dietary lipids from intestine to peripheral tissues (muscle, adipose).
VLDL Endogenous Hepatic Triglycerides (55-65%) ApoB-100 , ApoC-II, ApoE Delivers de novo hepatic triglycerides to peripheral tissues.
IDL Triglycerides and Cholesterol ApoB-100 , ApoE VLDL remnant; converted to LDL by hepatic lipase or taken up by liver.
LDL Cholesterol Esters (50%) ApoB-100 Delivers cholesterol to peripheral tissues via LDL-receptor endocytosis.
HDL Protein (50%), Phospholipids ApoA-I , ApoC-II, ApoE Executes reverse cholesterol transport (scavenges cholesterol from tissues to liver).
Key Apolipoproteins & Functions
ApoB-48: Mediates chylomicron secretion from enterocytes into lymphatics.
ApoB-100: Mediates VLDL assembly/secretion from hepatocytes; acts as ligand for LDL Receptor .
ApoC-II: Cofactor that activates Lipoprotein Lipase (LPL) on capillary endothelial surfaces, hydrolyzing triglycerides into free fatty acids and glycerol.
ApoE: Mediates remnant clearance by binding ApoE receptors on hepatocytes.
ApoA-I: Activates Lecithin-Cholesterol Acyltransferase (LCAT / PCAT) on HDL, esterifying free cholesterol for reverse transport.
Familial Hyperlipidemias
Type Inherited Disorder Defective Protein / Gene Pathophysiology & Clinical Manifestations
Type I Familial Hyperchylomicronemia Lipoprotein Lipase (LPL) or ApoC-II Severe elevation of chylomicrons and triglycerides in plasma. Recurrent acute pancreatitis , eruptive xanthomas , hepatosplenomegaly. No increased CAD risk. Creamy supernatant layer in standing plasma.
Type IIa Familial Hypercholesterolemia LDL Receptor ( L D L R LDLR L D L R ) or ApoB-100 Severe elevation of LDL and serum cholesterol. Accelerated premature coronary artery disease (CAD) , tendon xanthomas (Achilles tendon), and xanthelasma (palpebral). Heterozygotes cholesterol ≈ 300 mg/dL \approx 300\text{ mg/dL} ≈ 300 mg/dL ; Homozygotes ≈ 700 + mg/dL \approx 700+\text{ mg/dL} ≈ 700 + mg/dL (severe MI in childhood).
Type III Familial Dysbetalipoproteinemia ApoE2 homozygosity Impaired hepatic clearance of chylomicron remnants and IDL. Elevated chylomicron remnants and VLDL. Premature atherosclerosis, tuberoeruptive xanthomas , and palmar xanthomas (yellow palmar creases).